Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis
January 04, 2024 12:00 ET
|
CROSSJECT
Communiqué de presse Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis Crossject élargit ses activités d'accès au marché dans le cadre des...
Brain Implants Market to Attain a Valuation of USD 8.8 billion by 2031: Transparency Market Research Study
January 04, 2024 04:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The brain implants market was valued at US$ 4.2 billion in 2022. A CAGR of 8.4% is forecast...
Crossject signe un accord de commercialisation pour ZEPIZURE® en Europe du Nord
December 22, 2023 01:30 ET
|
CROSSJECT
Crossject recevra jusqu'à 1 million d'euros en vue des approbations de mise sur le marché, plus un multiple des coûts de production lié à la marge brute L'accord, signé avec un partenaire stratégique...
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
December 22, 2023 01:30 ET
|
CROSSJECT
Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner, allows Crossject to benefit from strong...
Global Deep Brain Stimulation Market Size to Reach USD 4.27 Billion in 2032 | Emergen Research
December 12, 2023 07:31 ET
|
Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global Deep Brain Stimulation (DBS) market, valued at USD 1.70 Billion in 2022, is projected to witness a robust revenue Compound Annual Growth Rate...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 05, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
December 04, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
December 01, 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
November 28, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
November 16, 2023 08:05 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...